Pazopanib in the treatment of advanced renal cell carcinoma
Pazopanib is an orally available multitargeted tyrosine kinase inhibitor (a class of targeted therapies) that inhibits tumor angiogenesis and cell proliferation. The safety and efficacy of pazopanib (noninferior to sunitinib for progression-free survival) in patients with advanced or metastatic rena...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2016-02-01
|
| Series: | Therapeutic Advances in Urology |
| Online Access: | https://doi.org/10.1177/1756287215614236 |
| _version_ | 1818912783272509440 |
|---|---|
| author | David Cella Jennifer L. Beaumont |
| author_facet | David Cella Jennifer L. Beaumont |
| author_sort | David Cella |
| collection | DOAJ |
| description | Pazopanib is an orally available multitargeted tyrosine kinase inhibitor (a class of targeted therapies) that inhibits tumor angiogenesis and cell proliferation. The safety and efficacy of pazopanib (noninferior to sunitinib for progression-free survival) in patients with advanced or metastatic renal cell carcinoma (mRCC) have been demonstrated in several clinical trials. However, in addition to therapeutic efficacy, treatment choices should also take into account health-related quality of life (HRQoL) aspects of cancer therapy. Here, we summarize the HRQoL findings related to pazopanib use, based on patient-reported outcome measures; pazopanib has been shown to be superior to sunitinib on several HRQoL domains (including patient preference). A further consideration for treatment choice is how well the findings from clinical trials correlate with evidence from general clinical practice. This review therefore includes descriptions of real-world experience of pazopanib use in the treatment of patients with mRCC, following its approval by medical regulatory authorities in a number of countries. Naturalistic observational studies demonstrate that the efficacy of pazopanib in patients with mRCC is consistent with clinical trial findings. Similarly, consistent results were observed for the safety profile of pazopanib between observational studies and clinical trials, with most treatment-associated adverse events being mild to moderate in severity, and manageable. |
| first_indexed | 2024-12-19T23:20:05Z |
| format | Article |
| id | doaj.art-30823c4cf4814e53aabaaa6f7d7a0269 |
| institution | Directory Open Access Journal |
| issn | 1756-2872 1756-2880 |
| language | English |
| last_indexed | 2024-12-19T23:20:05Z |
| publishDate | 2016-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Urology |
| spelling | doaj.art-30823c4cf4814e53aabaaa6f7d7a02692022-12-21T20:01:59ZengSAGE PublishingTherapeutic Advances in Urology1756-28721756-28802016-02-01810.1177/1756287215614236Pazopanib in the treatment of advanced renal cell carcinomaDavid CellaJennifer L. BeaumontPazopanib is an orally available multitargeted tyrosine kinase inhibitor (a class of targeted therapies) that inhibits tumor angiogenesis and cell proliferation. The safety and efficacy of pazopanib (noninferior to sunitinib for progression-free survival) in patients with advanced or metastatic renal cell carcinoma (mRCC) have been demonstrated in several clinical trials. However, in addition to therapeutic efficacy, treatment choices should also take into account health-related quality of life (HRQoL) aspects of cancer therapy. Here, we summarize the HRQoL findings related to pazopanib use, based on patient-reported outcome measures; pazopanib has been shown to be superior to sunitinib on several HRQoL domains (including patient preference). A further consideration for treatment choice is how well the findings from clinical trials correlate with evidence from general clinical practice. This review therefore includes descriptions of real-world experience of pazopanib use in the treatment of patients with mRCC, following its approval by medical regulatory authorities in a number of countries. Naturalistic observational studies demonstrate that the efficacy of pazopanib in patients with mRCC is consistent with clinical trial findings. Similarly, consistent results were observed for the safety profile of pazopanib between observational studies and clinical trials, with most treatment-associated adverse events being mild to moderate in severity, and manageable.https://doi.org/10.1177/1756287215614236 |
| spellingShingle | David Cella Jennifer L. Beaumont Pazopanib in the treatment of advanced renal cell carcinoma Therapeutic Advances in Urology |
| title | Pazopanib in the treatment of advanced renal cell carcinoma |
| title_full | Pazopanib in the treatment of advanced renal cell carcinoma |
| title_fullStr | Pazopanib in the treatment of advanced renal cell carcinoma |
| title_full_unstemmed | Pazopanib in the treatment of advanced renal cell carcinoma |
| title_short | Pazopanib in the treatment of advanced renal cell carcinoma |
| title_sort | pazopanib in the treatment of advanced renal cell carcinoma |
| url | https://doi.org/10.1177/1756287215614236 |
| work_keys_str_mv | AT davidcella pazopanibinthetreatmentofadvancedrenalcellcarcinoma AT jenniferlbeaumont pazopanibinthetreatmentofadvancedrenalcellcarcinoma |